Precision Ocular Metrology is a medical device startup dedicated to revolutionizing the way we measure ocular surface topography. Standard Placido disk slope measurements are great for optical power measurements on the central regions of the cornea but provide poor elevation topography, making them poor choices for specialty lens fitting. Our sMap3D topographer addresses this problem by providing direct anterior surface elevation measurements, letting you map the complete three-dimensional eye surface with an unprecedented 10 um precision.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Private Equity Round in 2020
Sonendo, Inc. is a company based in Laguna Hills, California, specializing in the development of innovative technologies for root canal therapy. The company manufactures the GentleWave® System, a cleaning technology that enhances the removal of tissues, debris, and bacteria from dental canals, demonstrating improved clinical efficacy and practice efficiency compared to traditional methods. Additionally, Sonendo is the parent company of TDO® Software, which provides widely used practice management software tailored for endodontic practices. This software integrates various functions, including imaging, social media, referral reporting, and communication with the GentleWave System, thereby streamlining workflow for dental professionals. Established in 2006, Sonendo aims to transform dentistry through advanced sound science.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Private Equity Round in 2017
Sonendo, Inc. is a company based in Laguna Hills, California, specializing in the development of innovative technologies for root canal therapy. The company manufactures the GentleWave® System, a cleaning technology that enhances the removal of tissues, debris, and bacteria from dental canals, demonstrating improved clinical efficacy and practice efficiency compared to traditional methods. Additionally, Sonendo is the parent company of TDO® Software, which provides widely used practice management software tailored for endodontic practices. This software integrates various functions, including imaging, social media, referral reporting, and communication with the GentleWave System, thereby streamlining workflow for dental professionals. Established in 2006, Sonendo aims to transform dentistry through advanced sound science.
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Sonendo, Inc. is a company based in Laguna Hills, California, specializing in the development of innovative technologies for root canal therapy. The company manufactures the GentleWave® System, a cleaning technology that enhances the removal of tissues, debris, and bacteria from dental canals, demonstrating improved clinical efficacy and practice efficiency compared to traditional methods. Additionally, Sonendo is the parent company of TDO® Software, which provides widely used practice management software tailored for endodontic practices. This software integrates various functions, including imaging, social media, referral reporting, and communication with the GentleWave System, thereby streamlining workflow for dental professionals. Established in 2006, Sonendo aims to transform dentistry through advanced sound science.
4Tech is a one-stop shop for plastic moldings and packaging solutions from design to manufacture. It was founded in 2011 and is based in Waltham, Massachusetts.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
Sonendo, Inc. is a company based in Laguna Hills, California, specializing in the development of innovative technologies for root canal therapy. The company manufactures the GentleWave® System, a cleaning technology that enhances the removal of tissues, debris, and bacteria from dental canals, demonstrating improved clinical efficacy and practice efficiency compared to traditional methods. Additionally, Sonendo is the parent company of TDO® Software, which provides widely used practice management software tailored for endodontic practices. This software integrates various functions, including imaging, social media, referral reporting, and communication with the GentleWave System, thereby streamlining workflow for dental professionals. Established in 2006, Sonendo aims to transform dentistry through advanced sound science.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
InDex Pharmaceuticals AB is a clinical-stage biopharmaceutical company based in Stockholm, Sweden, that focuses on developing treatments for ulcerative colitis and other immunological diseases. The company is known for its lead product, cobitolimod, which offers a local anti-inflammatory effect, aiding in mucosal healing and symptom improvement for patients with ulcerative colitis. InDex also utilizes its DNA-based ImmunoModulatory Sequences (DIMS) platform to create therapies targeting various inflammatory and oncological conditions. Additionally, the company provides DiBiCol, a diagnostic kit that identifies proprietary biomarkers for ulcerative colitis and Crohn's disease from a single colonic biopsy. Founded in 2016, InDex Pharmaceuticals operates as a subsidiary of InDex Pharmaceuticals Holding AB.
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.
Sonendo, Inc. is a company based in Laguna Hills, California, specializing in the development of innovative technologies for root canal therapy. The company manufactures the GentleWave® System, a cleaning technology that enhances the removal of tissues, debris, and bacteria from dental canals, demonstrating improved clinical efficacy and practice efficiency compared to traditional methods. Additionally, Sonendo is the parent company of TDO® Software, which provides widely used practice management software tailored for endodontic practices. This software integrates various functions, including imaging, social media, referral reporting, and communication with the GentleWave System, thereby streamlining workflow for dental professionals. Established in 2006, Sonendo aims to transform dentistry through advanced sound science.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Sonendo, Inc. is a company based in Laguna Hills, California, specializing in the development of innovative technologies for root canal therapy. The company manufactures the GentleWave® System, a cleaning technology that enhances the removal of tissues, debris, and bacteria from dental canals, demonstrating improved clinical efficacy and practice efficiency compared to traditional methods. Additionally, Sonendo is the parent company of TDO® Software, which provides widely used practice management software tailored for endodontic practices. This software integrates various functions, including imaging, social media, referral reporting, and communication with the GentleWave System, thereby streamlining workflow for dental professionals. Established in 2006, Sonendo aims to transform dentistry through advanced sound science.
Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.). Vessix is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.). Vessix is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Clavis Pharma ASA, a healthcare and clinical-stage pharmaceutical company, engages in the discovery and development of novel small molecule therapeutics for cancer and other unmet medical needs. It also engages in the development of new and improved pharmaceuticals based on its lipid vector technology (LVT). The company has three anti-cancer drugs in clinical development for various indications, and a pipeline of other drug candidates within oncology, virology, and anti-inflammatory diseases. Its products primarily include Elacytarabine, which is in the Phase II clinical trials for various solid tumor indications, as well as in Phase I/II clinical trials for the treatment of blood cancers, including leukemia; Intravenous CP-4126, a multicentre trial open to patients with any type of solid tumours that is in Phase I clinical trials; Oral CP-4126, an analogue of gemcitabine, which is Phase I clinical trial; and CP-4200, an epigenetic modulator that is in preclinical stage for the treatment of hematological malignancies, such as MDS and leukemia. The company�s products also include CP-4010, an analogue of acyclovir that is in the Phase I clinical trial for the treatment of herpes labialis and herpes genitalis; and CP-4018, an analogue of gancyclovir, which is in the preclinical stage. In addition, its products comprise CP-4033, CP-4112, and CP-4114 that are the analogues of ribavirin, betamethason, and prednisolon respectively. The company has a collaboration agreement with Mount Sinai School of Medicine for the design and testing of new LVT based drug candidates for the treatment of cancer and haematological malignancies. Clavis Pharma ASA was founded in 2001 and is headquartered in Oslo, Norway.
Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.
Creabilis SA is a clinical stage biotechnology company based in Luxembourg City, specializing in the research and development of new drugs for dermatology and inflammatory diseases. Founded in 2003, the company has developed a diverse pipeline of clinical and pre-clinical drug candidates, addressing significant unmet medical needs in skin disorders. Notable products in its portfolio include CT327, a TrkA kinase inhibitor aimed at treating psoriasis and atopic dermatitis; CT340, which targets both TrkA and MAP2K3 kinases for inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for various inflammatory conditions. Creabilis also engages in early-stage projects to explore additional treatment options. With research offices in Ivrea, Italy, and development operations in Canterbury, United Kingdom, the company aims to market its innovative therapies either independently or through partnerships.
PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine.
PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine.
Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.
Thommen Medical is a medical device company that specializes in the development, production, and sale of dental implants branded as SPI (Swiss Precision Implant). The company focuses on creating innovative and precisely designed implant systems that enhance patient comfort during surgical procedures and ensure long-term stability of the implants. Thommen Medical also offers biomaterial solutions for bone and tissue regeneration, collaborating with leading scientific and dental clinicians to improve the effectiveness and usability of its products. Through its commitment to design excellence and innovation, Thommen Medical aims to achieve optimal success for its clients in the field of dental implants.
Oxxon Therapeutics™ (Oxxon) is a company developing the next generation of innovative antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. To date, the company has built an initial pipeline through its patented Hi-8™ PrimeBoost immunotherapy platform, an approach that allows the rapid development of products to selectively stimulate and enhance potent immune responses against disease. The company has successfully completed phase II clinical programmes in melanoma and hepatitis B and has a third development programme underway in HIV. In addition, the company intends to leverage its enabling platform through partnerships with companies developing therapeutic and preventative vaccine products.
Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of products for the diagnosis and treatment of cardio-renal diseases. Discovery Therapeutics' product pipeline includes adenosine agonists and antagonists for the diagnosis and treatment of cardiovascular disease and leukotriene synthesis inhibitors for the treatment of chronic renal disease. In addition the company has license agreements with strategic partners involving novel late stage products for the treatment of Parkinson's disease and diagnosis of coronary artery disease.